Cellply at Advanced Therapies Week 2024
Cellply at Advanced Therapies Week 2024
Introducing VivaCyte
At single cell resolution, VivaCyte™ offers a dramatically improved level of understanding of immunotherapy mode of action, including relative potency. Our powerful platform delivers in-depth characterization of immune cell function, including serial killing, in combination with phenotypic analysis.
Taking cell therapy characterization and comparison to a new level.
Join Richard Harbottle and Evren Alici as they present their unique insights on how their labs utilize VivaCyte to rapidly identify the best TCR edits & validate a proprietary nanovector editing system; and hear how single cell characterization of immune cell function can be deployed in translational studies.
Hosted by Massimo Bocchi and Francesco Imperatore, these seminars are part of the formal fringe program of Advanced Therapies Week and open to all those interested in cell therapy characterization. The sessions will be held twice during the meeting so please sign up for the session that fits your timetable.
About Cellply
Based in Bologna, Cellply is the first Italian biotech to enter the market with a platform capable of measuring the effectiveness of cellular immunotherapies in the treatment of oncological diseases, paving the way in the fight against cancer. Thanks to Cellply’s technology, it will be possible to save the lives of even advanced-stage cancer patients through a system that optimizes development costs, controls the quality of cells delivered to the patient, and in the future will allow for monitoring of treated patients.